Combined EGFR/MEK inhibition prevents the emergence of resistance in EGFR-mutant lung cancer Academic Article uri icon

Overview

MeSH Major

  • Drug Resistance, Neoplasm
  • Lung Neoplasms
  • Mitogen-Activated Protein Kinase Kinases
  • Mutation
  • Protein Kinase Inhibitors
  • Receptor, Epidermal Growth Factor

abstract

  • Patients with EGFR-mutant lung cancer develop acquired resistance to EGFR and mutant-selective EGFR tyrosine kinase inhibitors. Here, we show that cotargeting EGFR and MEK can prevent the emergence of a broad variety of drug resistance mechanisms in vitro and in vivo and may be a superior therapeutic regimen for these patients.

publication date

  • September 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4824006

Digital Object Identifier (DOI)

  • 10.1158/2159-8290.CD-15-0063

PubMed ID

  • 26036643

Additional Document Info

start page

  • 960

end page

  • 71

volume

  • 5

number

  • 9